论文部分内容阅读
目的观察苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床疗效及安全性。方法将78例老年高血压伴血脂异常患者随机分为对照组39例与试验组39例。对照组予以晨起口服苯磺酸氨氯地平5 mg,qd;试验组在对照组的基础上,予以睡前口服阿托伐他汀钙10 mg。2组患者一个周期均为28 d,共治疗2个周期。比较2组患者的临床疗效、治疗前后的收缩压(SBP)、舒张压(DBP)、血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平以及不良反应发生情况。结果治疗后,试验组的总有效率为94.87%显著高于对照组的79.49%(P<0.05)。2组患者治疗后的SBP、DBP、TC、TG、LDL-C水平较治疗前显著降低,且试验组治疗后上述指标水平显著低于对照组(P<0.05)。试验组治疗后的HDL-C水平较治疗前显著升高(P<0.05),而对照组治疗前后的HDL-C水平比较差异无统计学意义(P>0.05),且试验组治疗后的HDL-C水平显著高于对照组(P<0.05)。对照组和试验组的不良反应发生率分别为7.69%和12.82%,差异无统计学意义(P>0.05)。结论苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床疗效显著,且不增加不良反应的发生率。
Objective To observe the clinical efficacy and safety of amlodipine besylate combined with atorvastatin calcium in the treatment of elderly patients with hypertension and dyslipidemia. Methods A total of 78 elderly hypertensive patients with dyslipidemia were randomly divided into control group (39 cases) and experimental group (39 cases). The control group was treated with amlodipine besylate 5 mg qd on the morning, and the experimental group was given oral atorvastatin 10 mg on the basis of the control group. One cycle of two groups of patients were 28 days, a total of 2 cycles. The clinical efficacy, SBP, DBP, TC, TG, HDL-C and LDL-C before and after treatment were compared between the two groups. The level of LDL-C and the incidence of adverse reactions. Results After treatment, the total effective rate of the experimental group was 94.87%, which was significantly higher than that of the control group (79.49%, P <0.05). The levels of SBP, DBP, TC, TG and LDL-C in the two groups were significantly lower than those before treatment, and the levels of these indexes in the two groups were significantly lower than those in the control group (P <0.05). The levels of HDL-C in experimental group were significantly higher than those before treatment (P <0.05), while there was no significant difference in HDL-C before and after treatment in experimental group (P> 0.05) -C level was significantly higher than the control group (P <0.05). The incidence of adverse reactions in the control group and experimental group were 7.69% and 12.82%, respectively, with no significant difference (P> 0.05). Conclusion The clinical efficacy of amlodipine besylate combined with atorvastatin calcium in treating elderly patients with hypertension and dyslipidemia is significant, and does not increase the incidence of adverse reactions.